Skip to content

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

  • Home
  • About US
  • Bioinsight
  • Policy Hub
  • Deals Book
  • Privacy Policy
  • Contact US

Header Toggle Sidebar

This is an example widget to show how the Header Toggle Sidebar looks by default. You can add custom widgets from the widgets in the admin.

Company Deals

CSPC Pharmaceutical’s Megalith Subsidiary Enters $1.77 Billion siRNA Collaboration with AstraZeneca for Novel RNAi Therapeutics

Fineline Cube Jul 3, 2026
Company Deals

Junshi Biosciences Licenses Anti-IL-17A Antibody Roconkibart to Fosun Wanbang for Greater China – $1.34B Deal Secures Commercialization of Phase III-Ready Psoriasis Therapy

Fineline Cube Jul 2, 2026
Company Deals Digital

Insilico Medicine and Takeda Launch $600M Strategic AI Drug Discovery Collaboration – Pharma.AI Platform to Drive Candidate Identification for High-Potential Therapeutic Targets

Fineline Cube Jul 2, 2026
Company Deals

Nona Biosciences and Lonza Forge Strategic Alliance to Develop Best-in-Class Blood-Brain Barrier Penetration Technology for CNS Therapeutics

Fineline Cube Jul 2, 2026
Company Deals

Ipsen to Acquire Memo Therapeutics for €200M Plus Milestones, Gaining Phase II BK Virus Antibody Potravitug for Transplant Nephropathy

Fineline Cube Jul 2, 2026
Policy / Regulatory

China’s CDE Unveils 108th Batch of Reference Preparations for Generic Drug Evaluation, Adds 28 New Drugs

Fineline Cube Jun 29, 2026
Company Drug

Hengrui Pharmaceuticals Secures NMPA Priority Review for Trastuzumab Rezetecan in HER2-Low Breast Cancer, Expanding Third Indication in China

Fineline Cube Jul 3, 2026
Company Drug

Edding Genor’s Trispecific Antibody GB268 Secures NMPA IND Approval for Phase Ib/II Breast Cancer Trial, Targeting TNBC and HR+/HER2- Subtypes

Fineline Cube Jul 3, 2026
Company Deals

Shenzhen Hepalink’s Subsidiary Techdow USA Secures Distribution Rights for ANDA-Approved Drug

Fineline Cube Apr 4, 2023

China-based Shenzhen Hepalink Pharmaceutical Group Co., Ltd (SHE: 002399) has announced that its wholly owned...

Company

SPH CanSinoBio Suspends COVID-19 Vaccine Production for 180 Days Amid Market Shifts

Fineline Cube Apr 4, 2023

SPH CanSinoBio, a joint venture between Shanghai Pharmaceuticals Group (SHA: 601607, HKG: 2607) and CanSino...

Company Deals

CNBG and Sinopharm Form Partnership to Integrate Medical Industries

Fineline Cube Apr 4, 2023

China National Biotec Group Company Ltd (CNBG) has announced a strategic partnership with its parent...

Company Deals

Beijing’s Surgerii Secures Series C3 Financing to Advance Endoscopic Surgical Robot Technology

Fineline Cube Apr 4, 2023

Beijing-based endoscopic surgical robot developer, Beijing Surgerii Robotics Company Limited, has reportedly raised hundreds of...

Company Drug

Lynk Pharmaceuticals Concludes Phase I Study for JAK Inhibitor LNK01003 with Positive Results

Fineline Cube Apr 4, 2023

China-based Lynk Pharmaceuticals (Hangzhou) Co., Ltd has announced the successful conclusion of a Phase I...

Company Deals

BioNTech and Duality Biologics Ink Exclusive License Agreement for ADC Assets

Fineline Cube Apr 4, 2023

Germany-based BioNTech SE (NASDAQ: BNTX) and China-headquartered Duality Biologics (Suzhou) Co., Ltd have announced that...

R&D

China’s Life Expectancy on Track to Surpass 81.3 Years by 2035, Study Reveals

Fineline Cube Apr 3, 2023

A recent study published in The Lancet has provided updated forecasts for life expectancy in...

Company Deals

Willingmed Secures Series B Funding to Advance Clinical Infection Diagnostics

Fineline Cube Apr 3, 2023

Willingmed, a Beijing-based company specializing in molecular biology for clinical infection precision diagnosis, has reportedly...

Policy / Regulatory

CDE Launches Guidelines to Expedite Pediatric and Rare Disease Drug Reviews

Fineline Cube Apr 3, 2023

The Center for Drug Evaluation (CDE) has unveiled a new set of “Work Specifications to...

Company Drug

Johnson & Johnson’s Talquetamab on Track for Breakthrough Therapy Designation in Multiple Myeloma

Fineline Cube Apr 3, 2023

China’s Center for Drug Evaluation (CDE) has indicated that US pharmaceutical giant Johnson & Johnson’s...

Company Drug

CSPC Pharmaceutical Receives FDA Approval for Phase I Study of CPO301 in Lung Cancer

Fineline Cube Apr 3, 2023

China-based CSPC Pharmaceutical Group Ltd (HKG: 1093) has announced that it has received approval from...

Company Drug

Shanghai Fosun Pharmaceutical Gets NMPA Approval for FCN-338 Phase II Study

Fineline Cube Apr 3, 2023

China-based Shanghai Fosun Pharmaceutical (Group) Co., Ltd (SHA: 600196, HKG: 2196) has announced receiving approval...

Company Drug

Mabwell Bioscience Receives NMPA Approval for Biosimilar Version of Amgen’s Prolia

Fineline Cube Apr 3, 2023

China-based Mabwell (Shanghai) Bioscience Co., Ltd (SHA: 688062) has announced receiving market approval from the...

Company Drug

Roche’s Cosentyx 300mg Dosage Approved by NMPA for Ankylosing Spondylitis Treatment

Fineline Cube Apr 3, 2023

Swiss pharmaceutical giant Roche (SWX: ROG) has announced that the National Medical Products Administration (NMPA)...

Company Drug

Changzhou Qianhong Bio-pharma Receives NMPA Approval for QHRD107 Phase II AML Study

Fineline Cube Apr 3, 2023

China-based Changzhou Qianhong Bio-pharma Co., Ltd (SHE: 002550) has announced obtaining approval from the National...

Company Drug

Konruns Pharmaceutical Reports Positive Efficacy Results for KC1036 in Advanced ESCC

Fineline Cube Apr 3, 2023

Beijing-based Konruns Pharmaceutical Co., Ltd (SHA: 603590) has announced the publication of efficacy study results...

Company Deals

Boao Lecheng Medical Tourism Zone Partners with Eye Valley to Advance Ophthalmology Innovation

Fineline Cube Apr 3, 2023

The Boao Lecheng Medical Tourism Pilot Zone in Hainan Province has announced a strategic partnership...

Company Drug

Cellular Biomedicine Group Initiates Phase III Study for AlloJoin in Knee Osteoarthritis

Fineline Cube Apr 3, 2023

China-based cell therapy specialist Cellular Biomedicine Group Inc. (CBMG) has announced the initiation of a...

Company Drug

Abbisko Therapeutics Secures Orphan Drug Designation for FGFR4 Inhibitor ABSK012

Fineline Cube Apr 3, 2023

Shanghai-based biotech Abbisko Therapeutics Co., Ltd (HKG: 2256) has announced that it has received orphan...

Company

Henlius Reports 91.1% Revenue Growth in 2022, Driven by Product Commercialization

Fineline Cube Apr 3, 2023

China-based Henlius (HKG: 2696) has announced its annual results for 2022, revealing that revenues reached...

Posts pagination

1 … 566 567 568 … 690

Recent updates

  • Hengrui Pharmaceuticals Secures NMPA Priority Review for Trastuzumab Rezetecan in HER2-Low Breast Cancer, Expanding Third Indication in China
  • Edding Genor’s Trispecific Antibody GB268 Secures NMPA IND Approval for Phase Ib/II Breast Cancer Trial, Targeting TNBC and HR+/HER2- Subtypes
  • Hengrui Pharmaceuticals Secures NMPA Priority Review for Trastuzumab Rezetecan in HER2-Low Breast Cancer, Expanding Third Indication in China
  • Shandong Boan Biotechnology Secures NMPA Approval for Phase II Trial of BA1106/BA1104 Combination in NSCLC, China’s First Non-IL-2-Blocking Anti-CD25 Antibody
  • CSPC Pharmaceutical’s Megalith Subsidiary Enters $1.77 Billion siRNA Collaboration with AstraZeneca for Novel RNAi Therapeutics
Special Report 2025 Q1: U.S. Targets Chinese Pharma with 200% Tariffs—Will the Global Drug Market Collapse?

Category

  • Company
  • Deals
  • Digital
  • Drug
  • General/Other
  • Hospital
  • Legal / IP
  • Medical Device
  • Others
  • Policy / Regulatory
  • R&D

You Missed

Company Drug

Hengrui Pharmaceuticals Secures NMPA Priority Review for Trastuzumab Rezetecan in HER2-Low Breast Cancer, Expanding Third Indication in China

Company Drug

Edding Genor’s Trispecific Antibody GB268 Secures NMPA IND Approval for Phase Ib/II Breast Cancer Trial, Targeting TNBC and HR+/HER2- Subtypes

Company Drug

Hengrui Pharmaceuticals Secures NMPA Priority Review for Trastuzumab Rezetecan in HER2-Low Breast Cancer, Expanding Third Indication in China

Company Drug

Shandong Boan Biotechnology Secures NMPA Approval for Phase II Trial of BA1106/BA1104 Combination in NSCLC, China’s First Non-IL-2-Blocking Anti-CD25 Antibody

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

Copyright © 2025 | Fineline Information & Technology | BlogData by Themeansar.